Edition:
India

Applied DNA Sciences Inc (APDN.OQ)

APDN.OQ on NASDAQ Stock Exchange Capital Market

1.33USD
19 Sep 2018
Change (% chg)

$0.09 (+7.26%)
Prev Close
$1.24
Open
$1.26
Day's High
$1.33
Day's Low
$1.26
Volume
46,124
Avg. Vol
10,727
52-wk High
$3.45
52-wk Low
$1.10

Latest Key Developments (Source: Significant Developments)

Applied DNA Sciences Shipped Over 8,000 Milligrams Of PCR-Produced Linear DNA In 12 Months
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Applied DNA Sciences Inc ::APPLIED DNA SCIENCES REACHES NEW MILESTONES IN THERAPEUTIC CONTRACT RESEARCH AND CONTRACT MANUFACTURING OF LINEAR DNA.APPLIED DNA SCIENCES - IN PAST 12 MONTHS, SHIPPED OVER 8,000 MILLIGRAMS OF PCR-PRODUCED LINEAR DNA.  Full Article

Wuhan Thalys Medical Technology and partner jointly sign contract with Pingdu People's Hospital
Monday, 8 Jan 2018 

Jan 8(Reuters) - Wuhan Thalys Medical Technology Inc <603716.SS>:Says it and China Resources Shandong Pharmaceutical Co Ltd jointly signed contract with Pingdu People's Hospital, regarding centralized purchasing and supply of test reagent and consumable.  Full Article

Wuhan Thalys Medical Technology signs contracts with Wuhan Hospital of Traditional Chinese Medicine
Monday, 8 Jan 2018 

Jan 8(Reuters) - Wuhan Thalys Medical Technology Inc <603716.SS>:Says it signed contracts with Wuhan Hospital of Traditional Chinese Medicine, regarding centralized delivery of test reagent and consumable.  Full Article

Applied DNA Sciences Q4 Revenue $1.1 Million
Friday, 29 Dec 2017 

Dec 28 (Reuters) - Applied Dna Sciences Inc ::APPLIED DNA SCIENCES REPORTS YEAR END AND FISCAL FOURTH QUARTER RESULTS.Q4 LOSS PER SHARE $0.10.Q4 REVENUE FELL 30 PERCENT TO $1.1 MILLION.  Full Article

Wuhan Thalys Medical Technology unit sets up medical tech unit in Tai'an City
Tuesday, 19 Dec 2017 

Dec 19(Reuters) - Wuhan Thalys Medical Technology Inc <603716.SS>:Says co's Jinan-based medical technology unit sets up a wholly owned medical technology unit in Tai'an City, with registered capital of 10 million yuan .  Full Article

Applied DNA And Colorcon To Collaborate To Commercialize Product Authentication Technology
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Applied Dna Sciences Inc ::APPLIED DNA AND COLORCON ANNOUNCE COLLABORATION TO COMMERCIALIZE PRODUCT AUTHENTICATION TECHNOLOGY FOR PHARMACEUTICAL AND NUTRACEUTICAL INDUSTRY.APPLIED DNA SCIENCES INC - CO, COLORCON INC HAVE ENTERED INTO A TECHNOLOGY LICENSE MEMORANDUM OF UNDERSTANDING.APPLIED DNA SCIENCES - DEAL TO COMMERCIALIZE PLATFORM FOR TRACEABILITY DIRECTLY ON DOSE, IS INTENDED TO REDUCE RISKS ASSOCIATED WITH COUNTERFEIT MEDICATIONS.  Full Article

Applied DNA Q4 Loss Per Share $0.10
Saturday, 16 Dec 2017 

Dec 15 (Reuters) - Applied DNA Sciences Inc ::APPLIED DNA ANNOUNCES SELECTED PRELIMINARY UNAUDITED FISCAL FOURTH QUARTER AND YEAR END RESULTS.Q4 LOSS PER SHARE $0.10.Q4 REVENUE FELL 30 PERCENT TO $1.1 MILLION.  Full Article

APPLIED DNA SECURES 1-YEAR CONTRACT EXTENSION WITH DEFENSE LOGISTICS AGENCY
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Applied DNA Sciences Inc ::APPLIED DNA SCIENCES INC - ‍DEFENSE LOGISTICS AGENCY (DLA) HAS AWARDED CO A ONE-YEAR EXTENSION OF ITS CURRENT CONTRACT THROUGH OCTOBER 13, 2018​.  Full Article

Double Medical Technology Inc sees FY 2017 net profit to up 20 pct to 40 pct
Friday, 27 Oct 2017 

Oct 27 (Reuters) - Double Medical Technology Inc <002901.SZ> ::Sees FY 2017 net profit to increase by 20 percent to 40 percent, or to be 263.2 million yuan to 307.1 million yuan.Says FY 2016 net profit was 219.3 million yuan.Says steady growth of main businesses as main reason for the forecast.  Full Article

BRIEF-Applied DNA Reports Q2 Loss Per Share Of $0.07

* APPLIED DNA REPORTS FISCAL SECOND QUARTER 2018 FINANCIAL RESULTS